Risedronic acid

Risedronic acid, often used as its sodium salt risedronate sodium, is a bisphosphonate.^[1] It slows down the cells which break down bone.^[1] It's used to treat or prevent osteoporosis, and treat Paget's disease of bone.^[1] It is taken by mouth.^[1]

Risedronic acid

Clinical data
Trade names	Actonel, Atelvia, Benet, others
AHFS/Drugs.com	Monograph
License data	US DailyMed: Risedronic
Pregnancy category	AU: B3
Routes of administration	By mouth
ATC code	M05BA07 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) US: ℞-only[1] In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	0.63%
Protein binding	~24%
Metabolism	None
Elimination half-life	1.5 h
Excretion	Kidney and fecal
Identifiers
IUPAC name (1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid
CAS Number	105462-24-6 Y
PubChem CID	5245
IUPHAR/BPS	3176
DrugBank	DB00884 N
ChemSpider	5055 N
UNII	KM2Z91756Z
KEGG	D00942 D03234
ChEMBL	ChEMBL923 N
PDB ligand	RIS (PDBe, RCSB PDB)
CompTox Dashboard (EPA)	DTXSID2023563
ECHA InfoCard	100.116.436
Chemical and physical data
Formula	C7H11NO7P2
Molar mass	283.113 g·mol−1
3D model (JSmol)	Interactive image
SMILES OC(Cc1cccnc1)(P(=O)(O)O)P(=O)(O)O
InChI InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15) N Key:IIDJRNMFWXDHID-UHFFFAOYSA-N N
NY (what is this?)  (verify)

It was patented in 1984 and approved for medical use in 1998.^[2]

Pharmacology

Relative potency^[3]

Bisphosphonate	Relative potency
Etidronate	1
Tiludronate	10
Pamidronate	100
Alendronate	100-500
Ibandronate	500-1000
Risedronate	1000
Zoledronate	5000

History

Risedronate, known as NE-58095 while under development, was discovered by scientists at the Cincinnati Miami Valley Laboratories and the Norwich Eaton Laboratories of Procter and Gamble. ^[4]

Society and culture

Brand names

It is produced and marketed by Warner Chilcott, Sanofi-Aventis, and in Japan by Takeda under the trade names Actonel, Atelvia, and Benet. It is also available in a preparation that includes a calcium carbonate supplement, as Actonel with Calcium.

Controversies

In January 2006 P&G and its marketing partner Sanofi-Aventis filed a Lanham Act false claims lawsuit against rival drugmakers Roche and GlaxoSmithKline claiming false advertising about Boniva.^[5] The manufacturers of Boniva, a rival bisphosphonate, were accused in the suit of causing a "serious public health risk" through misrepresentation of scientific findings. In a ruling on September 7, 2006, U.S. District Judge Paul A. Crotty rejected P&G's attempted injunction. P&G was criticized for attempting to "preserve its market share by denigrating Boniva". Judge Crotty wrote that "Roche was clearly entitled to respond with its own data, provided that the data was truthfully and accurately presented".^[6]

In 2006, P&G faced controversy over its handling of clinical research involving risedronate (News Reports^[7] and discussion).^[8]

In common with other bisphosphonate drugs, risedronate appears to be associated with the rare side effect osteonecrosis of the jaw, often preceded by dental procedures inducing trauma to the bone.